|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.810 HKD | +1.34% |
|
-0.20% | +16.37% |
| 01-15 | Pharma sector doubles down on AI amid hopes of slashing costs, timelines | RE |
| 01-15 | CSPC Innovation Pharmaceutical Warns of Swing to 2025 Loss | MT |
| Capitalization | 111B 14.19B 12.08B 11.22B 10.52B 19.59B 1,300B 20.77B 128B 50.76B 614B 53.22B 52.13B 2,247B | P/E ratio 2025 * |
20.2x | P/E ratio 2026 * | 18.6x |
|---|---|---|---|---|---|
| Enterprise value | 99.87B 12.81B 10.9B 10.12B 9.49B 17.68B 1,173B 18.74B 116B 45.8B 554B 48.03B 47.05B 2,028B | EV / Sales 2025 * |
3.25x | EV / Sales 2026 * | 3.02x |
| Free-Float |
70.45% | Yield 2025 * |
2.94% | Yield 2026 * | 3.21% |
| 1 day | +1.34% | ||
| 1 week | -0.20% | ||
| Current month | +16.37% | ||
| 1 month | +10.47% | ||
| 3 months | +19.49% | ||
| 6 months | +14.60% | ||
| Current year | +16.37% |
| 1 week | 9.54 |  | 10 |
| 1 month | 8.3 | | 10.16 |
| Current year | 8.38 | | 10.16 |
| 1 year | 4.33 | | 11.63 |
| 3 years | 4.27 | | 11.63 |
| 5 years | 4.27 | | 12.68 |
| 10 years | 3.08 | | 13.93 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lei Cai
CEO | Chief Executive Officer | 46 | 19/12/2025 |
Qing Jie Wei
COO | Chief Operating Officer | 57 | 19/12/2025 |
Zhi Yong Qu
PRN | Corporate Officer/Principal | 45 | 01/07/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Dong Chen Cai
CHM | Chairman | 72 | 26/08/2011 |
Huai Yu Wang
BRD | Director/Board Member | 63 | 01/10/2010 |
Zhen Guo Wang
BRD | Director/Board Member | 56 | 20/01/2012 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.34% | -0.20% | +124.49% | +4.70% | 14.19B | |
| +0.82% | +5.27% | +44.22% | +214.21% | 974B | |
| +0.22% | -0.49% | +50.40% | +29.48% | 526B | |
| +0.91% | +0.63% | +28.91% | +45.81% | 385B | |
| -0.17% | -0.49% | +26.53% | +17.52% | 376B | |
| +0.51% | -3.27% | +23.05% | +23.14% | 284B | |
| +0.43% | -0.07% | +27.99% | +35.22% | 279B | |
| -1.74% | -1.61% | +14.11% | -0.69% | 271B | |
| +2.00% | +3.90% | -30.46% | -16.30% | 277B | |
| +1.01% | +5.16% | +26.93% | +31.85% | 187B | |
| Average | +0.50% | +1.42% | +33.62% | +38.49% | 357.38B | |
| Weighted average by Cap. | +0.44% | +2.09% | +30.01% | +74.44% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 30.71B 3.94B 3.35B 3.11B 2.92B 5.44B 361B 5.76B 35.55B 14.09B 170B 14.77B 14.47B 624B | 32.48B 4.17B 3.55B 3.29B 3.09B 5.75B 382B 6.1B 37.6B 14.9B 180B 15.62B 15.3B 660B |
| Net income | 5.52B 708M 603M 560M 525M 978M 64.89B 1.04B 6.39B 2.53B 30.65B 2.66B 2.6B 112B | 6B 770M 655M 608M 570M 1.06B 70.5B 1.13B 6.95B 2.75B 33.3B 2.89B 2.83B 122B |
| Net Debt | -10.8B -1.38B -1.18B -1.09B -1.03B -1.91B -127B -2.03B -12.5B -4.95B -59.92B -5.19B -5.09B -219B | -12.63B -1.62B -1.38B -1.28B -1.2B -2.23B -148B -2.37B -14.61B -5.79B -70.06B -6.07B -5.95B -256B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 9.810 $ | +1.34% | 74,880,993 |
| 22/01/26 | 9.680 $ | -2.12% | 79,368,880 |
| 21/01/26 | 9.890 $ | +1.64% | 58,136,360 |
| 20/01/26 | 9.730 $ | -0.10% | 67,927,020 |
| 19/01/26 | 9.740 $ | -0.92% | 104,416,300 |
Delayed Quote Hong Kong S.E., January 23, 2026 at 12:08 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 1093 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition